Selective Use of Pulmonary Vasodilators in Patients with Fontan Physiology

BACKGROUND: Fontan-associated liver disease is a well-known sequela following the Fontan procedure for patients living with single-ventricle heart disease. Pulmonary vasodilators, such as phosphodiesterase type 5 inhibitors, have emerged as a potential therapeutic option for lowering central venous...

Descripción completa

Detalles Bibliográficos
Autores principales: Glenn, Thomas, Duster, Nicole, Dwek, Jerry, Silva-Sepulveda, Jose, El-Said, Howaida G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9671729/
https://www.ncbi.nlm.nih.gov/pubmed/36447937
http://dx.doi.org/10.1155/2022/7602793

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9671729/
https://www.ncbi.nlm.nih.gov/pubmed/36447937
http://dx.doi.org/10.1155/2022/7602793

Ejemplares similares